Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Lagundex - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Lagundex

Approved

STANDARD

Lagundex

La Croesus Pharma, Inc.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 9d9aa4f1c7c51a4e
Company: La Croesus Pharma, Inc.
Type: Standard

Approval Details

Approval Id: 9d9aa4f1c7c51a4e
Drug Approval Philippines Name: Lagundex
Product Name: Lagundex
Registration Number: HMR-37
Brand Name: Lagundex
Generic Name: Vitex negundo L. (Lagundi Leaf)
Dosage Form: Syrup (Lemon Orange)
Dosage Strength: 300 mg/5 mL
Manufacturer: La Croesus Pharma, Inc.
Trader: New Marketlink Pharmaceutical Corporation
Issuance Date: 24 January 2024
Expiry Date: 18 March 2029
Pharmacologic Category: Herbal Medicine (Anti-Cough/Anti-Asthma)
Classification: Household Remedy (HR)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

9d9aa4f1c7c51a4e

Type

Standard

Back to Philippines FDA Approvals